Quote | Reneo Pharmaceuticals Inc. (NASDAQ:RPHM)
Last: | $1.81 |
---|---|
Change Percent: | 0.0% |
Open: | $1.86 |
Close: | $1.81 |
High: | $1.87 |
Low: | $1.8 |
Volume: | 67,284 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
News | Reneo Pharmaceuticals Inc. (NASDAQ:RPHM)
2024-05-07 08:02:53 ET More on Reneo Pharmaceuticals Seeking Alpha’s Quant Rating on Reneo Pharmaceuticals Historical earnings data for Reneo Pharmaceuticals Financial information for Reneo Pharmaceuticals Read the full article on Seeking Alpha ...
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first qu...
Message Board Posts | Reneo Pharmaceuticals Inc. (NASDAQ:RPHM)
Subject | By | Source | When |
---|---|---|---|
Think we see 5 this week | heyitsmeagain | investorshub | 08/17/2022 2:10:21 PM |
Grabbed a bunch | heyitsmeagain | investorshub | 08/17/2022 11:00:00 AM |
Loaded boy Im pumped for this | heyitsmeagain | investorshub | 08/16/2022 6:40:48 PM |
A common factor among mitochondrial diseases is that | crudeoil24 | investorshub | 04/09/2021 2:14:40 PM |
Reneo Pharmaceuticals Shares Will Open For Quote At | crudeoil24 | investorshub | 04/09/2021 2:11:40 PM |
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first qu...
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical compa...